Amgen's T-VEC, a melanoma drug consisting of a modified version of the herpes virus, has been approved for use on the NHS, Daily Mail reported Friday.
In studies lead by the Institute of Cancer Research, the therapy was associated with an average overall survival of 41 months, compared to 21 months for another immunotherapy.
"It is very exciting news that NICE has approved T-VEC for patients with advanced melanoma, making it the first of its kind to be approved for use on the NHS," remarked Kevin Harrington of the Institute of Cancer Research," adding "this is the culmination of ten years’ work on this agent."
T-VEC has a list price of 3340 pounds to 13 360 pounds based on tumour size, although NHS will receive an undisclosed iscount.
"This positive recommendation adds to the number of promising new treatments for advanced melanoma NICE has recently recommended, providing patients with more options when faced with this form of skin cancer," commented a National Institute for Health and Care Excellence spokesperson.
To read more NewsPoints articles, click here.